BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 35645140)

  • 41. Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience.
    Sporea I; Mare R; Popescu A; Nistorescu S; Baldea V; Sirli R; Braha A; Sima A; Timar R; Lupusoru R
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32268517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. When the liver gets stiff, the tough get moving.
    Nguyen TH; Wardell R; Chitturi S; Teoh N; Farrell G
    J Gastroenterol Hepatol; 2020 Jun; 35(6):953-959. PubMed ID: 31867782
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease.
    Zhang W; Song WJ; Chen W; Pan Z; Zhang J; Fan L; Li J
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):802-810. PubMed ID: 38526946
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk factors associated with nonalcoholic fatty liver disease evaluated by elastography in patients with type 2 diabetes.
    Pozzan R; Pena RG; Palma CCSSV; de Carvalho Abi-Abib R; Terra C; Cobas RA
    Arch Endocrinol Metab; 2022 Sept 08; 66(4):452-458. PubMed ID: 35657127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Noninvasive tests for nonalcoholic fatty liver disease in a multi-ethnic population: The HELIUS study.
    van Dijk AM; Vali Y; Mak AL; Galenkamp H; Nieuwdorp M; van den Born BJ; Holleboom AG
    Hepatol Commun; 2023 Jan; 7(1):e2109. PubMed ID: 36333949
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between hypertension and the prevalence of liver steatosis and fibrosis.
    Fu H; Yu H; Zhao Y; Chen J; Liu Z
    BMC Endocr Disord; 2023 Apr; 23(1):85. PubMed ID: 37081417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.
    Avcu A; Kaya E; Yilmaz Y
    Turk J Gastroenterol; 2021 May; 32(5):466-472. PubMed ID: 34231477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population.
    Ciardullo S; Monti T; Grassi G; Mancia G; Perseghin G
    J Hypertens; 2021 Aug; 39(8):1621-1627. PubMed ID: 33657584
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan.
    Tuong TTK; Tran DK; Phu PQT; Hong TND; Dinh TC; Chu DT
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32183383
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
    J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years.
    Chen J; Hu P; Wang Y; Zhu Z
    BMC Endocr Disord; 2022 May; 22(1):128. PubMed ID: 35562689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.
    Long MT; Zhang X; Xu H; Liu CT; Corey KE; Chung RT; Loomba R; Benjamin EJ
    Hepatology; 2021 Feb; 73(2):548-559. PubMed ID: 33125745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus.
    Tan EZ; Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2021 Mar; 36(3):751-757. PubMed ID: 32583444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
    Lavynenko O; Abdul-Ghani M; Alatrach M; Puckett C; Adams J; Abdelgani S; Alkhouri N; Triplitt C; Clarke GD; Vasquez JA; Li J; Cersosimo E; Gastaldelli A; DeFronzo RA
    Diabetes Obes Metab; 2022 May; 24(5):899-907. PubMed ID: 35014145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advanced liver fibrosis predicts heart failure and hospitalizations in people with type 2 diabetes: A prospective cohort study from Hong Kong Diabetes Register.
    Kong AP; Lau ES; O CK; Luk AO; Yip TC; Chow EY; Kwok R; Lee HW; Wong GL; Ma RC; Chan HL; Wong VW; Chan JC
    Diabetes Res Clin Pract; 2023 Aug; 202():110825. PubMed ID: 37442241
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ALT poorly predicts Nonalcoholic Fatty Liver Disease (NAFLD) and liver fibrosis as determined by vibration-controlled transient elastography in adult National Health and Nutrition Examination Survey 2017-2018.
    Condon S; Hu H; Kong M; Cave MC; McClain CJ
    Am J Med Sci; 2024 May; 367(5):310-322. PubMed ID: 38307172
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Taheri H; Malek M; Ismail-Beigi F; Zamani F; Sohrabi M; Reza Babaei M; Khamseh ME
    Adv Ther; 2020 Nov; 37(11):4697-4708. PubMed ID: 32975679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation of hepatic transient elastography measurements and abdominal adiposity in children: A cross-sectional study.
    Lee YS; Song SH; Wu TC; Wu SL; Huang CF
    Pediatr Neonatol; 2023 Nov; 64(6):631-636. PubMed ID: 36967291
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
    Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
    Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.